THERAPY DOSSIER · th-04ae66ce5d4d

Torin2 and rapamycin

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24667246 ↗2014Mixed findings

Interleukin-6 secretion by astrocytes is dynamically regulated by PI3K-mTOR-calcium signaling.

RatSpinal cord injuryContusionSprague-DawleyMaleTreatment started two weeks after injury and continued for two weeks

Model: Contusion spinal cord injury; primary rat astrocyte cultures

Interleukin-6 was expressed by astrocytes and neurons one week after injury and then declined. Torin2 and rapamycin induced astrocyte interleukin-6 secretion in vitro, and treating injured animals from two weeks after injury produced only a modest effect on mechanical hypersensitivity that was limi…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…